INCA 33890-101: A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors
Part 1a: Histologically or cytologically confirmed advanced or metastatic solid tumors as follows: BC (pure small-cell carcinoma, pure adenocarcinoma, and pure squamous cell carcinoma are exlucded) - CESC - ESCA - GC - GEJ - Mel - MPM - NSCLC (mixed small-cell and non-small cell lung cancer histology is exlcluded - tumors should not exhibit mutations in EFGR, ALK, ROS1, BRAF) - OC (Sertoli-Leydic or germ cell cancers are excluded) - RCC - SCCHN (Carcinoma of the nasopharynx, salivary gland, or nonsquamous histologies are excluded) - TNBC - PAAD - CRC. Part1b: same as part 1a, plus dMMR/MSI-H CRC and MSS-CRC
|
I
|
CHUV
|